These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26324996)

  • 1. Vancomycin-Associated Nephrotoxicity: The Obesity Factor.
    Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Hennessy SA; Sawyer RG
    Surg Infect (Larchmt); 2015 Dec; 16(6):684-93. PubMed ID: 26324996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Top Guns: The "Maverick" and "Goose" of Empiric Therapy.
    Davies SW; Efird JT; Guidry CA; Dietch ZC; Willis RN; Shah PM; Sawyer RG
    Surg Infect (Larchmt); 2016 Feb; 17(1):38-47. PubMed ID: 26484854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity.
    Choi YC; Saw S; Soliman D; Bingham AL; Pontiggia L; Hunter K; Chuang L; Siemianowski LA; Ereshefsky B; Hollands JM
    Ann Pharmacother; 2017 Nov; 51(11):937-944. PubMed ID: 28709394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
    Rostas SE; Kubiak DW; Calderwood MS
    Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of a vancomycin dosage regimen developed for obese patients.
    Reynolds DC; Waite LH; Alexander DP; DeRyke CA
    Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
    Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
    J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*.
    Hanrahan TP; Harlow G; Hutchinson J; Dulhunty JM; Lipman J; Whitehouse T; Roberts JA
    Crit Care Med; 2014 Dec; 42(12):2527-36. PubMed ID: 25083977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections].
    Du B; Chen DC; Liu DW
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Jan; 15(1):32-4. PubMed ID: 12852813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
    Morrill HJ; Caffrey AR; Noh E; LaPlante KL
    Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of risk factors for nephrotoxicity associated with high-dose vancomycin in Japanese patients.
    Higashi T; Tsukamoto H; Kodawara T; Igarashi T; Watanabe K; Yano R; Iwasaki H; Goto N
    Pharmazie; 2021 Feb; 76(2):114-118. PubMed ID: 33714289
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China.
    Dong MH; Wang JW; Wu Y; Chen BY; Yu M; Wen AD
    Int J Infect Dis; 2015 Aug; 37():125-8. PubMed ID: 26159843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of Vancomycin to Cefazolin Prophylaxis Is Associated With Acute Kidney Injury After Primary Joint Arthroplasty.
    Courtney PM; Melnic CM; Zimmer Z; Anari J; Lee GC
    Clin Orthop Relat Res; 2015 Jul; 473(7):2197-203. PubMed ID: 25421958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.
    Ingram PR; Lye DC; Fisher DA; Goh WP; Tam VH
    Int J Antimicrob Agents; 2009 Dec; 34(6):570-4. PubMed ID: 19744837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates.
    Constance JE; Balch AH; Stockmann C; Linakis MW; Korgenski EK; Roberts JK; Ward RM; Sherwin CM; Spigarelli MG
    Arch Dis Child Fetal Neonatal Ed; 2016 May; 101(3):F236-43. PubMed ID: 26400103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
    Matson KL; Shaffer CL; Beck GL; Simonsen KA
    Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin-induced acute kidney injury detected by a prospective pharmacovigilance program from laboratory signals.
    Ramírez E; Jiménez C; Borobia AM; Tong HY; Medrano N; Krauel-Bidwell L; Carcas AJ; Selgas R; Frías J
    Ther Drug Monit; 2013 Jun; 35(3):360-6. PubMed ID: 23666575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.